Multidrug resistance in Cancer: Stratagem view and current challanges
-
Chair(s):
Prof. Chiara Riganti,
Associate professor, MD,Department of Oncology, Torino, Italy ,Prof. Javier De Las Rivas
Full Professor, PhD,Cancer Research Center, University of Salamanca, Salamanca, Spain -
Session description:
Dissecting the MDR with an European perspective: discovering STRATAGEM and PANDORA projects
Professor Chiara Riganti
Associate professor, MD, Department of Oncology, Torino, ItalyComputational biology and OMICS data mining in MDR: a matter of networking
Professor Javier De Las Rivas
Full Professor, PhD, Cancer Research Center, University of Salamanca, Salamanca, SpainBiological and pharmacological underpinnings of therapeutic resistance in pancreatic cancer
Professor Elisa Giovannetti
Laboratory of Medical Oncology, Medical University of Amsterdam, The NetherlandsApplications of Aptamer-Based Targeted Nanocarriers for cancer
Professor Bilge Guvenc Tuna
Associate professor, PhD, University of Angers/INSERM 066 CNRS 6021, Angers, FranceEfficacy versus safety: what is most important in MDR reversing agents?
Dr Yordan Yordanov
Research associate, Faculty of Pharmacy, Medical University Sofia, Sofia, BulgariaThe perspective of a clinical oncologist; dealing with resistant tumours
Dr Elisabeth Pérez-Ruiz
MD, Oncology Unit, Hospital Costa del Sol, Malaga, Spain
Speakers
-
Dr Elisabeth Pérez-RuizMD,Oncology Unit, Hospital Costa del Sol, Malaga, Spain
-
Dr Yordan YordanovResearch Associate, Faculty of Pharmacy, Medical University Sofia, Sofia, Bulgaria
-
Professor Bilge Guvenc Tuna
-
Professor Chiara RigantiAssociate professor, MD,Department of Oncology, Torino, Italy
-
Professor Elisa GiovannettiLaboratory of Medical Oncology, Medical University of Amsterdam, The Netherlands
-
Professor Javier De Las RivasFull Professor, PhD,Cancer Research Center, University of Salamanca, Salamanca, Spain
Leave A Comment